全文获取类型
收费全文 | 29871篇 |
免费 | 1968篇 |
国内免费 | 420篇 |
专业分类
耳鼻咽喉 | 743篇 |
儿科学 | 471篇 |
妇产科学 | 482篇 |
基础医学 | 4737篇 |
口腔科学 | 472篇 |
临床医学 | 2316篇 |
内科学 | 6052篇 |
皮肤病学 | 941篇 |
神经病学 | 2050篇 |
特种医学 | 2204篇 |
外科学 | 4278篇 |
综合类 | 139篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 978篇 |
眼科学 | 993篇 |
药学 | 2557篇 |
中国医学 | 402篇 |
肿瘤学 | 2438篇 |
出版年
2024年 | 16篇 |
2023年 | 147篇 |
2022年 | 558篇 |
2021年 | 1189篇 |
2020年 | 569篇 |
2019年 | 831篇 |
2018年 | 1018篇 |
2017年 | 746篇 |
2016年 | 1171篇 |
2015年 | 1570篇 |
2014年 | 1858篇 |
2013年 | 2110篇 |
2012年 | 2953篇 |
2011年 | 2696篇 |
2010年 | 1739篇 |
2009年 | 1435篇 |
2008年 | 1888篇 |
2007年 | 1747篇 |
2006年 | 1540篇 |
2005年 | 1323篇 |
2004年 | 1039篇 |
2003年 | 903篇 |
2002年 | 853篇 |
2001年 | 328篇 |
2000年 | 263篇 |
1999年 | 202篇 |
1998年 | 130篇 |
1997年 | 105篇 |
1996年 | 90篇 |
1995年 | 72篇 |
1994年 | 65篇 |
1993年 | 61篇 |
1992年 | 105篇 |
1991年 | 115篇 |
1990年 | 94篇 |
1989年 | 81篇 |
1988年 | 79篇 |
1987年 | 112篇 |
1986年 | 71篇 |
1985年 | 65篇 |
1984年 | 42篇 |
1983年 | 37篇 |
1982年 | 30篇 |
1981年 | 25篇 |
1980年 | 16篇 |
1979年 | 22篇 |
1978年 | 36篇 |
1976年 | 11篇 |
1975年 | 11篇 |
1974年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
L W Brady C Miyamoto D V Woo M Rackover J Emrich H Bender S Dadparvar Z Steplewski H Koprowski P Black 《International journal of radiation oncology, biology, physics》1992,22(1):225-230
Twenty-five patients with primary presentation of malignant astrocytoma, astrocytoma with anaplastic foci, and glioblastoma multiforme were treated with surgical resection and definitive radiation therapy followed by intravenous or intra-arterial administration of Iodine-125 labeled monoclonal antibody-425, which binds specifically to human epidermal growth factor receptor. The patients presented with primary untreated disease, positive contrast enhanced computed tomography scans of the brain, and compatible clinical symptoms. In this Phase II clinical trial, the patients had surgical debulking or biopsy followed by definitively administered external beam radiation therapy and one or multiple doses (35 to 90 mCi per infusion) of radiolabeled antibody. The total cumulative doses ranged from 40 to 224 mCi. The administrations of the radiolabeled antibody were performed in most cases 4-6 weeks following completion of the primary surgery and radiation therapy. Ten patients had astrocytoma with anaplastic foci and 15 had glioblastoma multiforme. No significant life-threatening toxicities were observed during this trial. At 1 year 60% of the patients with astrocytoma with anaplastic foci or glioblastoma multiforme are alive. The median survival for both groups was 15.6 months. 相似文献
32.
J. K. Kang Sang Won Lee Min Woo Baik Byung Chul Son Yong Kil Hong Chul Ku Jung Keon Hee Ryu 《Child's nervous system》1998,14(7):297-301
Accurate assessment and replacement of blood loss and fluid–electrolyte deficit during craniosynostosis repair is difficult
owing to patient size and the diversity of surgical technique. Forty-three patients undergoing primary craniosynostosis repair
over a 10-year period were studied retrospectively to determine blood loss and fluid deficit and to assess blood transfusion
practices during both intraoperative and postoperative periods. Blood loss was calculated on the basis of estimated red cell
mass (ERCM) and fluid-electrolyte imbalance was investigated with blood samplings. Blood transfusion was considered appropriate
if the postoperative or posttransfusion ERCM was within 12% of the preoperative value. Estimated fluid requirement (EFR) was
used in 4 ml kg–1 h–1 except for neonates. Intraoperatively, 80% of all patients were appropriately managed with respect to blood transfusion and
EFR. Postoperatively only 20% of the patients receiving transfusions were transfused appropriately. In 23.3% of these patients
(10/43) unexpected respiratory distress developed immediately after their recovery from the anesthesia. With the measurement
of estimated blood volume and allowable blood loss, appropriate transfusion could be achieved for the successful treatment
of the primary craniosynostosis.
Received: 16 February 1998 相似文献
33.
34.
35.
36.
Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. 总被引:6,自引:0,他引:6
Joo Hyun Kang June-Key Chung Yong Jin Lee Jae Hoon Shin Jae Min Jeong Dong Soo Lee Myung Chul Lee 《Journal of nuclear medicine》2004,45(9):1571-1576
To evaluate the possibility of radionuclide gene therapy and imaging in hepatocellular carcinoma cancer, we investigated the iodine accumulation of a human hepatocellular carcinoma cell line, SK-Hep1, by transfer of human sodium iodide symporter (hNIS) gene. By targeting NIS expression in SK-Hep1, we could also investigate whether these cells concentrate 99mTc-pertechnetate and 188Re-perrhenate as well as 125I in vitro and in vivo. METHODS: The hNIS gene was transfected to human hepatocellular carcinoma SK-Hep1 cell lines using lipofectamine plus reagent. The uptake and efflux of 125I, 99mTc-pertechnetate, and 188Re-perrhenate were measured in the transfected and parental cells. Biodistribution was studied in nude mice bearing SK-Hep1 and SK-Hep1-NIS at 10 and 30 min and at 1, 2, 6, 16, and 23 h after injection of 125I, 99mTc- pertechnetate, or 188Re-perrhenate. In tumor imaging studies, the nude mice were intravenously injected with 188Re-perrhenate and imaged with a gamma-camera equipped with a pinhole collimator at 30 and 60 min after injection. The survival rate (%) was determined by the clonogenic assay after 37 MBq/10 mL (1 mCi/10 mL) 131I and 188Re-perrhenate treatment. RESULTS: SK-Hep1-NIS, stably expressing the NIS gene, accumulated 125I up 150 times higher than that of SK-Hep1. Iodine uptake of SK-Hep1-NIS is completely blocked by perchlorate. NIS gene transfection into SK-Hep1 also resulted in 112- and 87-fold increases of 99mTc-pertechnetate and 188Re-perrhenate uptake, respectively. Iodide efflux from SK-Hep1-NIS was relatively slow, with only 10% released during the initial 5 min, and 60% remained at 25 min. In the biodistribution study using SK-Hep1-NIS-xenographed mice, the tumor uptake of 125I, 188Re-perrhenate, and 99mTc-pertechnetate was 68.0 +/- 15.0, 46.2 +/- 9.1, and 59.6 +/- 16.2 %ID/g (percentage injected dose per gram) at 2 h after injection, respectively. After 188Re-perrhenate injection in SK-Hep1 and SK-Hep1-NIS-xenographed nude mice, whole-body images clearly visualized the SK-Hep1-NIS tumor, whereas the control tumor was not visualized. The survival rate (%) of SK-Hep1-NIS was markedly reduced to 46.3% +/- 10.1% and 28.9% +/- 5.2% after 37 MBq/mL (1 mCi/10 mL) 131I and 188Re-perrhenate treatment compared with the survival rates of the parental cells. These results demonstrated that SK-Hep1-NIS could be selectively killed by the induced 131I and 188Re-perrhenate accumulation through NIS gene expression. CONCLUSION: NIS-based gene therapy using beta-emitting radionuclides has the potential to be used in hepatocellular carcinoma management. 相似文献
37.
38.
Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction
BLT2, a low-affinity leukotriene B4 (LTB4) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2iL3) and the Gαi3 protein subunit (Gαi3), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules—purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC50 = 1.6 μM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC50 = 0.42 μM for BLT2]—as specific BLT2-blocking agents. We found that blockade of the BLT2iL3-Gαi3 interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB4-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2iL3 and Gαi3 and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases. 相似文献
39.
40.